Skip to Content

Travivo Approval Status

FDA Approved: No
Brand name: Travivo
Generic name: gepirone
Company: Fera Pharmaceuticals
Treatment for: Depression, Major Depressive Disorder

Travivo (gepirone extended-release) is an investigational azapirone antidepressant in development for the treatment of adults with major depressive disorder.

Development Status and FDA Approval Process for Travivo

DateArticle
Mar 17, 2016FDA Rules Favorably On Efficacy Of Travivo (Gepirone ER) For Treatment Of Major Depressive Disorder
Dec  2, 2015Fabre-Kramer Looks Forward to FDA's Decision on Gepirone ER for the Treatment of Major Depressive Disorder
Nov  5, 2007Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
May  8, 2007Fabre-Kramer Refiles Gepirone ER with the FDA for the Treatment of Major Depressive Disorder

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide